Swaminath Anand, Knox Jennifer J, Brierley James D, Dinniwell Rob, Wong Rebecca, Kassam Zahra, Kim John, Coolens Catherine, Brock Kristy K, Dawson Laura A
Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):729-37. doi: 10.1016/j.ijrobp.2015.12.015. Epub 2015 Dec 17.
The purpose of this study was to quantify unexpected liver volume reductions in patients treated with sorafenib prior to and during liver radiation therapy (RT).
Fifteen patients were treated in a phase 1 study of sorafenib for 1 week, followed by concurrent sorafenib-RT (in 6 fractions). Patients had either focal cancer (treated with stereotactic body RT [SBRT]) or diffuse disease (treated with whole-liver RT). Liver volumes were contoured and recorded at planning (day 0) from the exhale CT. After 1 week of sorafenib (day 8), RT image guidance at each fraction was performed using cone beam CT (CBCT). Planning liver contours were propagated and modified on the reconstructed exhale CBCT. This was repeated in 12 patients treated with SBRT alone without sorafenib. Three subsequent patients (2 sorafenib-RT and 1 non-sorafenib) were also assessed with multiphasic helical breath-hold CTs.
Liver volume reductions on CBCT were observed in the 15 sorafenib-RT patients (median decrease of 68 cc, P=.02) between day 0 and 8; greater in the focal (P=.025) versus diffuse (P=.52) cancer stratum. Seven patients (47%) had reductions larger than the 95% intraobserver contouring error. Liver reductions were also observed from multiphasic CTs in the 2 additional sorafenib-RT patients between days 0 and 8 (decreases of 232.5 cc and 331.7 cc, respectively) and not in the non-sorafenib patient (increase of 92 cc). There were no significant changes in liver volume between planning and first RT in 12 patients with focal cancer treated with SBRT alone (median increase, 4.8 cc, P=.86).
Liver volume reductions were observed after 7 days of sorafenib, prior to RT, most marked in patients with focal liver tumors, suggesting an effect of sorafenib on normal liver. Careful assessment of potential liver volume changes immediately prior to SBRT may be necessary in patients in sorafenib or other targeted therapies.
本研究旨在量化在肝放射治疗(RT)之前及期间接受索拉非尼治疗的患者肝脏意外体积减少情况。
15例患者参加了索拉非尼的1期研究,先接受1周索拉非尼治疗,随后进行索拉非尼与RT同步治疗(分6次)。患者患有局灶性癌症(接受立体定向体部放疗[SBRT])或弥漫性疾病(接受全肝RT)。在计划阶段(第0天)从呼气CT上勾勒并记录肝脏体积。索拉非尼治疗1周后(第8天),每次分割使用锥形束CT(CBCT)进行RT图像引导。在重建的呼气CBCT上传播并修改计划肝脏轮廓。12例仅接受SBRT而未接受索拉非尼治疗的患者也进行了同样操作。另外3例患者(2例索拉非尼与RT联合治疗和1例非索拉非尼治疗)也通过多期螺旋屏气CT进行了评估。
在第0天至第8天之间,15例索拉非尼与RT联合治疗的患者在CBCT上观察到肝脏体积减少(中位数减少68 cc,P = 0.02);在局灶性癌症组(P = 0.025)比弥漫性癌症组(P = 0.52)更明显。7例患者(47%)的肝脏体积减少大于观察者自身轮廓勾画误差的95%。另外2例索拉非尼与RT联合治疗的患者在第0天至第8天之间通过多期CT也观察到肝脏体积减少(分别减少232.5 cc和331.7 cc),而非索拉非尼治疗的患者肝脏体积增加了92 cc。12例仅接受SBRT治疗的局灶性癌症患者在计划阶段与首次RT之间肝脏体积无显著变化(中位数增加4.8 cc,P = 0.86)。
在RT之前,索拉非尼治疗7天后观察到肝脏体积减少,在局灶性肝肿瘤患者中最为明显,提示索拉非尼对正常肝脏有影响。对于接受索拉非尼或其他靶向治疗的患者,在SBRT之前可能需要仔细评估潜在的肝脏体积变化。